“More Accurate Diagnoses Through Machine Learning” An Interview with Marco Rogg
Why is ARCONDIS the right partner for the Digital Transformation?
We are doing so well because we combine our extensive life sciences know-how and interdisciplinary understanding with information technology expertise. To be more specific, our consultants possess life science expertise in the areas of research, development, and technical operations. We combine this with IT expertise and an understanding of compliance issues. It is this combination which allows us to successfully support the Digital Transformation of our customers. Therefore, I strongly support to expand this interdisciplinary understanding even further. It differentiates ARCONDIS and is an expression of our strength.
You mentioned innovation projects – could you tell us more about that?
In the case of digital biomarkers, this specific project deals with the development of apps and the use of wearables for the evaluation of digitally recorded data concerning the condition of a patient during a clinical study. We are currently working on these projects with our customers. We are also forging ahead with the development of a digital operating model for an international pharmaceutical company. We have developed a service catalog for digital services as well as an operating model that provides the agility required for innovation.
Whether it’s cloud platforms, internet of things or real world data – compliance always plays an important role for the life sciences industry. There is often a great deal of uncertainty as to how Digital Transformation can be reconciled with the regulatory requirements. What is your advice for pharmaceutical and medical device companies?
The key challenge is often the question: How can I combine digital innovation, which requires agility, with compliance, which often follows a traditional sequential waterfall model?
This is where agile validation can help. The main thing is to involve compliance departments in the planning process at an early stage to keep an eye on relevant regulatory requirements from the outset. This is where clients can benefit from the wide range of services offered by ARCONDIS. Every single consultant knows about the compliance requirements; it has become part of our DNA. Moreover, at ARCONDIS, we have around twenty consultants who are specialized exclusively in compliance and are also contributing greatly to agile validation. In other words, combining innovation and compliance is exactly what we are good at.
For the future, we are assuming that regulatory requirements will change drastically to keep up with technological advances, which will open the door for additional new digital business models. This process already started. A few years ago, for example, the use of fitness-tracker data was inconceivable. Today, as already mentioned, there are pilot projects based around the collection and evaluation of these readings, i.e., of digital biomarkers for clinical trials.
Advances in the field of digitization will continue to accelerate and lead to entirely new questions. For the near future, it is foreseeable that such systems will significantly help physicians to provide more reliable diagnoses. For many people, it is still unthinkable that one day the diagnosis will also be supported by artificial intelligence and, ultimately, might even be completely provided by it. An AI [editor’s note: Artificial Intelligence] can access more extensive data sets and will be able to make more informed diagnoses through ” machine learning “. This substantial advantage for patients coupled with rapidly rising costs in the health care system will create the necessary pressure to realize this change.
To round off, please complete the following sentence: To me, enthusing customers means …
… anticipating what the customer needs to be successful but which he is not yet aware of – this will help him to achieve his personal and company goals. As consultants, we see many complex customer situations and have the right experience to understand them and recommend the right measures.